{"id":"https://openalex.org/W2809105267","doi":"https://doi.org/10.1186/s13023-018-0841-3","title":"Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia","display_name":"Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia","alternate_titles":[],"publication_year":2018,"publication_date":"2018-06-20","ids":{"openalex":"https://openalex.org/W2809105267","doi":"https://doi.org/10.1186/s13023-018-0841-3","mag":"2809105267","pmid":"https://pubmed.ncbi.nlm.nih.gov/29925433","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/6011273"},"language":"en","primary_location":{"id":"doi:10.1186/s13023-018-0841-3","doi":"https://doi.org/10.1186/s13023-018-0841-3","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s13023-018-0841-3","pdf_url":"https://ojrd.biomedcentral.com/track/pdf/10.1186/s13023-018-0841-3","source":{"id":"https://openalex.org/S71291065","display_name":"Orphanet Journal of Rare Diseases","issn_l":"1750-1172","issn":["1750-1172"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Orphanet Journal of Rare Diseases","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2809105267"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://ojrd.biomedcentral.com/track/pdf/10.1186/s13023-018-0841-3","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5078515650","display_name":"Dirk Jacobus Blom","orcid":"https://orcid.org/0000-0003-3965-5912","observed_orcids":["https://orcid.org/0000-0003-3965-5912"]},"institutions":[{"id":"https://openalex.org/I157614274","display_name":"University of Cape Town","ror":"https://ror.org/03p74gp79","country_code":"ZA","type":"education","lineage":["https://openalex.org/I157614274"]}],"countries":["ZA"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Dirk J. Blom","raw_affiliation_strings":["Division of Lipidology, Department of Medicine, University of Cape Town, Cape Town, South Africa. dirk.blom@uct.ac.za","Division of Lipidology, Department of Medicine, University of Cape Town, Cape Town, South Africa"],"raw_orcid":"https://orcid.org/0000-0003-3965-5912","affiliations":[{"raw_affiliation_string":"Division of Lipidology, Department of Medicine, University of Cape Town, Cape Town, South Africa. dirk.blom@uct.ac.za","institution_ids":["https://openalex.org/I157614274"]},{"raw_affiliation_string":"Division of Lipidology, Department of Medicine, University of Cape Town, Cape Town, South Africa","institution_ids":["https://openalex.org/I157614274"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037375815","display_name":"Marina Cuchel","orcid":"https://orcid.org/0000-0001-6808-3824","observed_orcids":["https://orcid.org/0000-0001-6808-3824"]},"institutions":[{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Marina Cuchel","raw_affiliation_strings":["Institute for Translational Medicine and Therapeutics, Cardiovascular Institute, University of Pennsylvania, Philadelphia, PA, 19104, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institute for Translational Medicine and Therapeutics, Cardiovascular Institute, University of Pennsylvania, Philadelphia, PA, 19104, USA","institution_ids":["https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036005993","display_name":"M. Ager","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Miranda Ager","raw_affiliation_strings":["Arduvo Ltd, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Arduvo Ltd, London, UK","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5089045688","display_name":"Helen Phillips","orcid":"https://orcid.org/0000-0002-4406-4394","observed_orcids":["https://orcid.org/0000-0002-4406-4394"]},"institutions":[{"id":"https://openalex.org/I4210147981","display_name":"Acacia Pharma (United Kingdom)","ror":"https://ror.org/03x1kdq06","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210147981"]},{"id":"https://openalex.org/I4210165317","display_name":"Cyclerion (United States)","ror":"https://ror.org/05tzg1b68","country_code":"US","type":"company","lineage":["https://openalex.org/I4210165317"]}],"countries":["GB","US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Helen Phillips","raw_affiliation_strings":["Aegerion Pharmaceuticals Ltd, Uxbridge, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Aegerion Pharmaceuticals Ltd, Uxbridge, UK","institution_ids":["https://openalex.org/I4210147981","https://openalex.org/I4210165317"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5078515650"],"corresponding_institution_ids":["https://openalex.org/I157614274"],"apc_list":{"value":2990,"currency":"USD","value_usd":2990},"apc_paid":{"value":2990,"currency":"USD","value_usd":2990},"fwci":3.9687,"has_fulltext":true,"cited_by_count":44,"citation_normalized_percentile":{"value":0.94771812,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"13","issue":"1","first_page":"96","last_page":"96"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13430","display_name":"Lipid metabolism and disorders","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11618","display_name":"Cholesterol and Lipid Metabolism","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lomitapide","display_name":"lomitapide","score":0.890999972820282},{"id":"https://openalex.org/keywords/homozygous-familial-hypercholesterolemia","display_name":"homozygous familial hypercholesterolemia","score":0.9959999918937683},{"id":"https://openalex.org/keywords/ldl-cholesterol-targets","display_name":"LDL cholesterol targets","score":0.7979999780654907},{"id":"https://openalex.org/keywords/major-adverse-cardiovascular-events","display_name":"major adverse cardiovascular events","score":0.968999981880188},{"id":"https://openalex.org/keywords/cardiovascular-risk-reduction","display_name":"cardiovascular risk reduction","score":0.6480000019073486},{"id":"https://openalex.org/keywords/mipomersen","display_name":"mipomersen","score":0.9470000267028809},{"id":"https://openalex.org/keywords/evolocumab","display_name":"evolocumab","score":0.9980000257492065},{"id":"https://openalex.org/keywords/pcsk9-inhibitors","display_name":"PCSK9 inhibitors","score":0.8289999961853027},{"id":"https://openalex.org/keywords/ldl-cholesterol-lowering","display_name":"LDL cholesterol lowering","score":0.531000018119812},{"id":"https://openalex.org/keywords/extension-trial","display_name":"extension trial","score":0.5139999985694885},{"id":"https://openalex.org/keywords/lipid-lowering-therapy","display_name":"lipid-lowering therapy","score":0.6359999775886536},{"id":"https://openalex.org/keywords/cardiovascular-mortality","display_name":"cardiovascular mortality","score":0.5270000100135803},{"id":"https://openalex.org/keywords/coronary-artery-bypass-grafting","display_name":"coronary artery bypass grafting","score":0.972000002861023}],"concepts":[{"id":"https://openalex.org/C2780739214","wikidata":"https://www.wikidata.org/wiki/Q6723023","display_name":"Mace","level":4,"score":0.8511912822723389},{"id":"https://openalex.org/C2778114629","wikidata":"https://www.wikidata.org/wiki/Q15623825","display_name":"Evolocumab","level":5,"score":0.7774568200111389},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7451767921447754},{"id":"https://openalex.org/C2779120738","wikidata":"https://www.wikidata.org/wiki/Q2711291","display_name":"Familial hypercholesterolemia","level":3,"score":0.6945993304252625},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5722788572311401},{"id":"https://openalex.org/C2780948078","wikidata":"https://www.wikidata.org/wiki/Q21130010","display_name":"PCSK9","level":5,"score":0.5575166344642639},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.4932834506034851},{"id":"https://openalex.org/C2780902209","wikidata":"https://www.wikidata.org/wiki/Q4726914","display_name":"Alirocumab","level":5,"score":0.4930684268474579},{"id":"https://openalex.org/C2780072125","wikidata":"https://www.wikidata.org/wiki/Q28350","display_name":"Lipoprotein","level":3,"score":0.3452855050563812},{"id":"https://openalex.org/C2778163477","wikidata":"https://www.wikidata.org/wiki/Q43656","display_name":"Cholesterol","level":2,"score":0.32877838611602783},{"id":"https://openalex.org/C500558357","wikidata":"https://www.wikidata.org/wiki/Q12152","display_name":"Myocardial infarction","level":2,"score":0.2914058566093445},{"id":"https://openalex.org/C43554185","wikidata":"https://www.wikidata.org/wiki/Q425649","display_name":"LDL receptor","level":4,"score":0.11491289734840393},{"id":"https://openalex.org/C45393284","wikidata":"https://www.wikidata.org/wiki/Q191012","display_name":"Conventional PCI","level":3,"score":0.07070288062095642},{"id":"https://openalex.org/C2780745583","wikidata":"https://www.wikidata.org/wiki/Q1316030","display_name":"Apolipoprotein A1","level":4,"score":0.0}],"mesh":[{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001026","descriptor_name":"Coronary Artery Bypass","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001562","descriptor_name":"Benzimidazoles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001562","descriptor_name":"Benzimidazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006720","descriptor_name":"Homozygote","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006938","descriptor_name":"Hyperlipoproteinemia Type II","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D006938","descriptor_name":"Hyperlipoproteinemia Type II","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006938","descriptor_name":"Hyperlipoproteinemia Type II","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D008078","descriptor_name":"Cholesterol, LDL","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009841","descriptor_name":"Oligonucleotides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D009841","descriptor_name":"Oligonucleotides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":6,"locations":[{"id":"doi:10.1186/s13023-018-0841-3","doi":"https://doi.org/10.1186/s13023-018-0841-3","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s13023-018-0841-3","pdf_url":"https://ojrd.biomedcentral.com/track/pdf/10.1186/s13023-018-0841-3","source":{"id":"https://openalex.org/S71291065","display_name":"Orphanet Journal of Rare Diseases","issn_l":"1750-1172","issn":["1750-1172"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Orphanet Journal of Rare Diseases","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:4969271","doi":null,"is_oa":true,"landing_page_url":"http://europepmc.org/pmc/articles/PMC6011273","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"","raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:6011273","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6011273/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Orphanet J Rare Dis","raw_type":"Text"},{"id":"pmid:29925433","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29925433","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Orphanet journal of rare diseases","raw_type":"Clinical Trial, Phase III"},{"id":"pmh:oai:doaj.org/article:d016379f4d1042c6b28471ae61a292a9","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/d016379f4d1042c6b28471ae61a292a9","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Orphanet Journal of Rare Diseases, Vol 13, Iss 1, Pp 1-6 (2018)","raw_type":"article"},{"id":"pmh:oai:localhost:11427/28293","doi":null,"is_oa":false,"landing_page_url":"http://hdl.handle.net/11427/28293","pdf_url":null,"source":{"id":"https://openalex.org/S4306402129","display_name":"Open University of Cape Town (University of Cape Town)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I157614274","host_organization_name":"University of Cape Town","host_organization_lineage":["https://openalex.org/I157614274"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Orphanet Journal of Rare Diseases","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1186/s13023-018-0841-3","doi":"https://doi.org/10.1186/s13023-018-0841-3","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s13023-018-0841-3","pdf_url":"https://ojrd.biomedcentral.com/track/pdf/10.1186/s13023-018-0841-3","source":{"id":"https://openalex.org/S71291065","display_name":"Orphanet Journal of Rare Diseases","issn_l":"1750-1172","issn":["1750-1172"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Orphanet Journal of Rare Diseases","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2809105267.pdf","grobid_xml":"https://content.openalex.org/works/W2809105267.grobid-xml"},"referenced_works_count":12,"referenced_works":["https://openalex.org/W1970935527","https://openalex.org/W2023735564","https://openalex.org/W2102238081","https://openalex.org/W2142526970","https://openalex.org/W2165791625","https://openalex.org/W2346771470","https://openalex.org/W2588614813","https://openalex.org/W2734434515","https://openalex.org/W2754692890","https://openalex.org/W3205881446","https://openalex.org/W4251822284","https://openalex.org/W6803647287"],"related_works":["https://openalex.org/W4206437067","https://openalex.org/W7171787218","https://openalex.org/W3035783349","https://openalex.org/W3198320369","https://openalex.org/W4409016267","https://openalex.org/W4226470452","https://openalex.org/W4403228567","https://openalex.org/W4213360317","https://openalex.org/W4386247444","https://openalex.org/W3072652402"],"abstract_inverted_index":{"BACKGROUND:":[0],"Homozygous":[1],"familial":[2],"hypercholesterolaemia":[3],"(HoFH)":[4],"is":[5,37],"characterized":[6],"by":[7,312],"a":[8],"markedly":[9],"increased":[10],"risk":[11],"of":[12,49,60,82,93,96,128,143,159,201,216,247,260,277],"premature":[13],"cardiovascular":[14],"(CV)":[15],"events":[16,36,76,196,272,308],"and":[17,34,122,131,140,162,185,208,220,222,232,238,245,263,323],"cardiac":[18,183],"death.":[19],"Lomitapide":[20],"reduces":[21],"low-density":[22],"lipoprotein":[23],"cholesterol":[24],"(LDL-C)":[25],"levels;":[26],"however,":[27],"the":[28,45,50,100,111,116,144,150,169,179,289,299],"probable":[29],"impact":[30],"on":[31],"LDL-C":[32,65,126,157,227,258,314],"goals":[33,259],"CV":[35,75,271,307],"unknown.":[38],"METHODS:":[39],"We":[40,67],"used":[41,68],"data":[42,71],"collected":[43],"in":[44,99,110,149,178,214,279,288,309],"first":[46,117],"26":[47,118],"weeks":[48],"lomitapide":[51,101,180,251],"pivotal":[52],"phase":[53,112],"3":[54,113],"study":[55,152,171],"(NCT00730236)":[56],"to":[57,85,194,293],"evaluate":[58],"achievement":[59],"European":[61],"Atherosclerosis":[62],"Society":[63],"(EAS)":[64],"targets.":[66],"publicly":[69],"available":[70],"reporting":[72],"major":[73,270],"adverse":[74],"(MACE)":[77],"rates":[78,88,204],"from":[79],"other":[80],"cohorts":[81,215],"HoFH":[83,217,310],"patients":[84,107,146,218,248,280,311],"compare":[86],"event":[87],"for":[89,235,252],"an":[90],"equivalent":[91,193],"number":[92],"patient":[94,199,275],"years":[95,256],"exposure":[97],"(98)":[98],"extension":[102,151],"trial":[103],"(NCT00943306).":[104],"RESULTS:":[105],"Twenty-nine":[106],"were":[108,176,205,229,268],"included":[109],"study.":[114],"During":[115],"weeks,":[119],"15":[120],"(51%)":[121],"eight":[123],"(28%)":[124],"reached":[125,156,257],"targets":[127,158],"100":[129,160,261],"mg/dL":[130,161,164,234,262],"70":[132,163,264],"mg/dL,":[133,265],"respectively,":[134],"at":[135,165,253],"least":[136,166,254],"once.":[137],"Fourteen":[138],"(74%)":[139],"11":[141],"(58%)":[142],"19":[145],"who":[147,249],"remained":[148],"after":[153],"week":[154],"126":[155],"once":[167],"during":[168],"entire":[170],"period.":[172],"Only":[173],"two":[174],"MACE":[175,203],"reported":[177,287],"trials":[181],"(one":[182],"death":[184],"one":[186],"coronary":[187],"artery":[188],"bypass":[189],"graft":[190],"(CABG))":[191],"-":[192],"1.7":[195],"per":[197,210,273],"1000":[198,211,274],"months":[200,276],"treatment.":[202],"21.7,":[206],"9.5":[207],"1.8":[209],"patient-months":[212],"respectively":[213],"pre-":[219],"post-mipomersen,":[221],"receiving":[223],"evolocumab.":[224],"On":[225],"treatment":[226,278],"levels":[228],"166,":[230],"331":[231],"286":[233],"lomitapide,":[236,282],"mipomersen":[237,283,290],"evolocumab,":[239],"respectively.":[240,266],"CONCLUSIONS:":[241],"Approximately":[242],"three":[243],"quarters":[244],"half":[246],"took":[250],"2":[255],"There":[267],"fewer":[269],"taking":[281],"or":[284],"evolocumab":[285],"than":[286],"cohort":[291],"prior":[292],"starting":[294],"mipomersen.":[295],"These":[296],"results":[297],"support":[298],"hypothesis":[300],"that":[301],"novel":[302],"lipid-lowering":[303],"therapies":[304],"may":[305],"reduce":[306],"lowering":[313],"further.":[315],"TRIAL":[316],"REGISTRATION:":[317],"NCT00730236":[318],"(registered":[319,325],"8":[320],"Aug":[321],"2008)":[322],"NCT00943306":[324],"22":[326],"July":[327],"2009).":[328]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2809105267","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":7},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":9},{"year":2019,"cited_by_count":6},{"year":2018,"cited_by_count":1}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2018-06-29T00:00:00"}
